Product Description
For Schizophrenia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02205099)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SK Life Science, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02205099 |
SKL15508C003 | P2 |
Completed |
Schizophrenia |
2015-06-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|